JP2022548803A - Prebiotic composition rich in dietary fiber containing mushroom extract and probiotic composition containing the same - Google Patents
Prebiotic composition rich in dietary fiber containing mushroom extract and probiotic composition containing the same Download PDFInfo
- Publication number
- JP2022548803A JP2022548803A JP2021516768A JP2021516768A JP2022548803A JP 2022548803 A JP2022548803 A JP 2022548803A JP 2021516768 A JP2021516768 A JP 2021516768A JP 2021516768 A JP2021516768 A JP 2021516768A JP 2022548803 A JP2022548803 A JP 2022548803A
- Authority
- JP
- Japan
- Prior art keywords
- dietary fiber
- weight
- parts
- rich
- prebiotic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 144
- 239000000284 extract Substances 0.000 title claims abstract description 109
- 235000001674 Agaricus brunnescens Nutrition 0.000 title claims abstract description 107
- 235000013325 dietary fiber Nutrition 0.000 title claims abstract description 99
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 88
- 239000006041 probiotic Substances 0.000 title claims abstract description 30
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 30
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 30
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 128
- 241000894006 Bacteria Species 0.000 claims abstract description 65
- 239000004310 lactic acid Substances 0.000 claims abstract description 64
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 64
- 235000000346 sugar Nutrition 0.000 claims abstract description 24
- 238000000605 extraction Methods 0.000 claims description 31
- 239000000654 additive Substances 0.000 claims description 29
- 230000000996 additive effect Effects 0.000 claims description 26
- 240000008397 Ganoderma lucidum Species 0.000 claims description 24
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 229920001542 oligosaccharide Polymers 0.000 claims description 18
- 240000000599 Lentinula edodes Species 0.000 claims description 17
- 150000002482 oligosaccharides Chemical class 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- 235000008476 powdered milk Nutrition 0.000 claims description 11
- 235000020185 raw untreated milk Nutrition 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 239000008213 purified water Substances 0.000 claims description 10
- 229920001353 Dextrin Polymers 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 9
- 235000019425 dextrin Nutrition 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 235000013336 milk Nutrition 0.000 claims description 8
- 239000008267 milk Substances 0.000 claims description 8
- 210000004080 milk Anatomy 0.000 claims description 8
- 244000298479 Cichorium intybus Species 0.000 claims description 6
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 5
- 240000001462 Pleurotus ostreatus Species 0.000 claims description 5
- 235000001603 Pleurotus ostreatus Nutrition 0.000 claims description 5
- 229940039696 lactobacillus Drugs 0.000 claims description 5
- 235000020183 skimmed milk Nutrition 0.000 claims description 5
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 244000103635 Lyophyllum ulmarium Species 0.000 claims description 4
- 235000015934 Lyophyllum ulmarium Nutrition 0.000 claims description 4
- 241000272503 Sparassis radicata Species 0.000 claims description 4
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 235000018185 Betula X alpestris Nutrition 0.000 claims description 3
- 235000018212 Betula X uliginosa Nutrition 0.000 claims description 3
- 241000208421 Ericaceae Species 0.000 claims description 3
- 240000006499 Flammulina velutipes Species 0.000 claims description 3
- 235000016640 Flammulina velutipes Nutrition 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 235000001715 Lentinula edodes Nutrition 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- 235000008939 whole milk Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 31
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 22
- 210000004369 blood Anatomy 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 13
- 230000012010 growth Effects 0.000 abstract description 8
- 230000003579 anti-obesity Effects 0.000 abstract description 7
- 230000001629 suppression Effects 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 5
- 210000000936 intestine Anatomy 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 235000013618 yogurt Nutrition 0.000 description 14
- 244000252132 Pleurotus eryngii Species 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 235000009200 high fat diet Nutrition 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 235000015140 cultured milk Nutrition 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- 244000028550 Auricularia auricula Species 0.000 description 2
- 235000000023 Auricularia auricula Nutrition 0.000 description 2
- 241000222511 Coprinus Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- -1 ergosterin Natural products 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- 244000251953 Agaricus brunnescens Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- QSVJYFLQYMVBDR-UHFFFAOYSA-N Ergosterin Natural products C1C(O)CCC2(C)C3=CCC4(C)C(C(C)C=CC(C)C(C)C)CCC4C3=CC=C21 QSVJYFLQYMVBDR-UHFFFAOYSA-N 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 241000123330 Fomes fomentarius Species 0.000 description 1
- 240000000588 Hericium erinaceus Species 0.000 description 1
- 235000007328 Hericium erinaceus Nutrition 0.000 description 1
- 241001534815 Hypsizygus marmoreus Species 0.000 description 1
- 241000414067 Inonotus obliquus Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000001727 Tropicoporus linteus Species 0.000 description 1
- 241000338179 Umbilicaria esculenta Species 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- DNVPQKQSNYMLRS-APGDWVJJSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-APGDWVJJSA-N 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
- A23L31/10—Yeasts or derivatives thereof
- A23L31/15—Extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5114—Dextrins, maltodextrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5116—Other non-digestible fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dairy Products (AREA)
Abstract
キノコ抽出物を含むプレバイオティクス組成物及びこれを含むプロバイオティクス組成物に関するもので、前記プレバイオティクス組成物は3次抽出したキノコ抽出物を含むことで食物繊維が豊富な特性がある。又、これを含むプロバイオティクス組成物は乳酸菌の菌株の増殖が容易で豊富な乳酸菌の菌株を保有しているので、乳酸菌の整腸作用及び免疫力向上等の効能だけではなく食物繊維による血糖上昇抑制及び血中コレストロール数値降下効果等抗肥満効果を表する特性がある。The present invention relates to a prebiotic composition containing a mushroom extract and a probiotic composition containing the same, wherein the prebiotic composition contains a tertiary extracted mushroom extract and is rich in dietary fiber. In addition, since the probiotic composition containing this contains an abundance of lactic acid bacteria that facilitate the growth of lactic acid bacteria, the probiotic composition contains not only the effects of lactic acid bacteria such as regulating the intestines and improving immunity, but also blood sugar by dietary fiber. It has anti-obesity effects such as suppression of elevation and lowering of blood cholesterol levels.
Description
本発明はキノコ抽出物を含むプレバイオティクス組成物及びこれを含むプロバイオティクス組成物に関するもので、前記プレバイオティクス組成物は3次抽出したキノコ抽出物を含むことで食物繊維が豊富な特性がある。又、これを含むプロバイオティクス組成物は乳酸菌の菌株の増殖が容易で、豊富な乳酸菌の菌株を保有しているので、乳酸菌の整腸作用及び免疫力向上等の効能だけではなく食物繊維による血糖上昇抑制及び血中コレストロール数値降下効果等抗肥満効果を表する特性がある。 The present invention relates to a prebiotic composition containing a mushroom extract and a probiotic composition containing the same, wherein the prebiotic composition contains a tertiary extracted mushroom extract and is rich in dietary fiber. There is In addition, the probiotic composition containing this facilitates the growth of lactic acid bacteria strains and has abundant lactic acid bacteria strains, so not only the effects of lactic acid bacteria such as intestinal regulation and immunity improvement, but also the effects of dietary fiber It has anti-obesity properties such as blood sugar elevation suppression and blood cholesterol lowering effect.
現代社会の科学及び医学発達によって人類平均寿命が日々増加しているが食習慣の変化、ストレス、運動量不足等による肥満、糖尿、高血圧のような成人病発病率が一緒に増加している。このような問題を解決するために最新医薬研究がコツコツとなっているし、天然物質探索及びこれを利用した健康機能食品開発研究も又活発に行われている。 With the development of science and medicine in modern society, the average life expectancy of mankind is increasing day by day, but the incidence of adult diseases such as obesity, diabetes, and hypertension is also increasing due to changes in eating habits, stress, and lack of exercise. In order to solve these problems, the latest medical research is being carried out diligently, and the search for natural substances and the development of health functional foods using the natural substances are also being actively carried out.
日常的に摂取している食材の中でも健康増進及び維持に効果的な生理活性物質を含有しているが、この中食用及び薬用と広く利用されているキノコ類が生理活性物質として大きな関心を得ている。 Among foods that are consumed on a daily basis, they contain physiologically active substances that are effective in promoting and maintaining health.Mushrooms, which are widely used for both edible and medicinal purposes, are of great interest as physiologically active substances. ing.
キノコは糖質、たんぱく質、ビタミン、アミノ酸、無機質等のように人体に重要な各種栄養素を満遍なく含有しているし、免疫増強、抗癌、抗ウィルス、抗糖尿、抗血栓、抗高血圧等の生理活性効果が明かされて健康機能食品又は機能性食品として生産と消費増加趨勢を見せている。 Mushrooms evenly contain various nutrients important to the human body, such as carbohydrates, proteins, vitamins, amino acids, and minerals. Its active effect has been revealed, and its production and consumption are increasing as a health functional food or functional food.
一方、発酵乳は原乳又は乳加工品(牛乳製品)を乳酸菌、酵母で発酵させたもので、牛乳の栄養成分以外にプロバイオティクス乳酸菌の作用によって生成された有機酸、アミノ酸、ペプチド、微量の生理活性物質と乳酸菌体が含まれていて、食品としての栄養だけではなく、腸内有害細菌の抑制と腸の機能性向上、腸内細菌叢の均衡維持と整腸作用、免疫系の刺激による抗癌効果、血中コレストロール低下効果等現代人の成人病予防と健康増進に卓越した機能を表すると報告されている。 On the other hand, fermented milk is produced by fermenting raw milk or processed milk products (milk products) with lactic acid bacteria and yeast. containing physiologically active substances and lactic acid bacteria, it is not only nutritious as a food, but also suppresses harmful intestinal bacteria, improves intestinal functionality, maintains the balance of intestinal flora, regulates the intestines, and stimulates the immune system. It is reported that it has excellent functions in preventing adult diseases and promoting health in modern people, such as anticancer effects and blood cholesterol lowering effects.
これによって機能性物質が添加された色んな形態の発酵乳製品開発が行われていて、発酵乳の機能性だけではなく食品としての嗜好度増進と新しい生理活性が強化された発酵乳に対する研究が活発に行われている。 As a result, various types of fermented milk products with added functional substances are being developed, and active research is being conducted on fermented milk that not only has functionality but also enhances palatability as food and has enhanced physiological activity. is done in
このような生理活性が強化された発酵乳の例としては韓国登録特許第10-0476302号の“成人病予防用発酵乳及びその製造方法”及び韓国公開特許第10-2017-0036254号の“肝機能改善用椎茸発酵物の製造方法”を挙げられる。 Examples of fermented milk with enhanced physiological activity include Korean Patent No. 10-0476302 entitled "Fermented Milk for Prevention of Adult Diseases and Method for Producing the Same" and Korean Patent Publication No. 10-2017-0036254 entitled "Hepatic Milk". Method for producing fermented shiitake mushrooms for improving function”.
しかし、前記先行文献のようにキノコ抽出物を含有する発酵乳に対する技術たちが開発されているが、従来と同じ方法で製造された発酵乳に含有された食物繊維を見ると、ほとんど水溶性食物繊維含有量より不溶性食物繊維含有量が桁外れに高いことと表れる。 However, although the technology for fermented milk containing mushroom extract has been developed as in the prior art, the dietary fiber contained in the fermented milk produced by the same method as the conventional method is mostly water-soluble food. It appears that the insoluble dietary fiber content is much higher than the fiber content.
これに従って、飲食物を胃腸に長くとどまるようにして、血糖が徐々に上昇するようにするし、インシュリンが一気に分泌されるのを防止できる生理活性機能を持つ水溶性食物繊維含有量がより高い発酵乳製品に対する研究開発が急な実情である。 According to this, the food is fermented with a higher content of water-soluble dietary fiber, which has a bioactive function that allows food to stay in the gastrointestinal tract for a long time, gradually increases blood sugar, and prevents insulin from being secreted at once. Research and development of dairy products is in a hurry.
本発明は前記した従来技術の問題点を解決するために案出されたもので、キノコ抽出物及び添加剤を含む、食物繊維が豊富なプレバイオティクス及びこれの製造方法を提供することにその目的がある。 DISCLOSURE OF THE INVENTION The present invention was devised to solve the above-mentioned problems of the prior art, and aims to provide prebiotics rich in dietary fiber containing mushroom extracts and additives, and a method for producing the same. have a purpose.
又、前記プレバイオティクス組成物及び乳酸菌の菌株を含むプロバイオティクス組成物及びこれの製造方法を提供することにその目的がある。 Another object of the present invention is to provide a probiotic composition comprising the prebiotic composition and a strain of lactic acid bacteria, and a method for producing the same.
前述した技術的課題を達成するための技術的手段として、本発明の一側面は、 As a technical means for achieving the technical problems described above, one aspect of the present invention is
キノコ抽出物及び添加剤を含むプレバイオティクス組成物として、前記キノコ抽出物はマンネンタケ(Lingzhi mushroom)抽出物を含むことであり、前記添加剤は原乳、粉乳(粉ミルク)、糖及びこれらの組み合わせからなる群から選択される物質を含むことであり、前記プレバイオティクス組成物は前記キノコ抽出物100重量部対比食物繊維の含量が30重量部以上であることを特徴とする食物繊維が豊富なプレバイオティクス組成物を提供する。 A prebiotic composition comprising a mushroom extract and an additive, wherein the mushroom extract comprises Lingzhi mushroom extract, and the additive comprises raw milk, milk powder (milk powder), sugar and combinations thereof. wherein the prebiotic composition contains 30 parts by weight or more of dietary fiber relative to 100 parts by weight of the mushroom extract. A prebiotic composition is provided.
前記食物繊維の含量は前記キノコ抽出物100重量部対比60重量部乃至80重量部であることを特徴とするものであってよい。 The content of the dietary fiber may be 60 to 80 parts by weight based on 100 parts by weight of the mushroom extract.
前記食物繊維は水溶性食物繊維及び不溶性食物繊維を含むことであり、前記食物繊維全体100重量部対比前記水溶性食物繊維の含量は40重量部乃至80重量部であり、前記不溶性食物繊維の含量は20重量部乃至60重量部であることを特徴とするものであってよい。 The dietary fiber contains water-soluble dietary fiber and insoluble dietary fiber, the content of the water-soluble dietary fiber is 40 to 80 parts by weight with respect to 100 parts by weight of the total dietary fiber, and the content of the insoluble dietary fiber is 20 to 60 parts by weight.
前記キノコ抽出物は前記マンネンタケ抽出物以外に、椎茸(Lentinula edodes)、エリンギ(King Oyster Mushroom)、エノキタケ(Enoki mushroom)、ヒラタケ(Oyster mushroom)、マッシュルーム(Agaricus bisporus)、メシマコブ(Phellinus linteus)、ブナシメジ(Hypsizygus marmoreus)、ハナビラタケ(Sparassis crispa)、カバノアナタケ(チャーガ、Inonotus obliquus)、ヤマブシタケ(Hericium erinaceus)及びこれらの組み合わせからなる群から選択されるキノコの抽出物を更に含むことを特徴とするものであってよい。 In addition to the Ganoderma lucidum extract, the mushroom extracts include Lentinula edodes, King Oyster Mushroom, Enoki mushroom, Oyster mushroom, Agaricus bisporus, Phellinus linteus, and Bunashimeji. (Hypsizygus marmoreus), Sparassis crispa, Chaga (Inonotus obliquus), Hericium erinaceus and a combination thereof. you can
前記キノコ抽出物の含量は前記添加剤100重量部対比400重量部乃至600重量部であることを特徴とするものであってよい。 The content of the mushroom extract may be 400 to 600 parts by weight based on 100 parts by weight of the additive.
前記粉乳は全脂粉乳及び脱脂粉乳から選択される少なくともいずれか一つであることを特徴とするものであってよい。 The milk powder may be at least one selected from whole milk powder and skimmed milk powder.
前記糖は単糖類、二糖類、糖アルコール類、オリゴ糖類、デキストリン及びこれらの組み合わせからなる群から選択される糖を含むことを特徴とするものであってよい。 The sugars may be characterized by comprising sugars selected from the group consisting of monosaccharides, disaccharides, sugar alcohols, oligosaccharides, dextrins and combinations thereof.
前記オリゴ糖類はフラクトオリゴ糖、マルトオリゴ糖、イソマルトオリゴ糖、ガラクトオリゴ糖、大豆オリゴ糖及びこれらの組み合わせからなる群から選択されるオリゴ糖を含むことを特徴とするものであってよい。 The oligosaccharides may be characterized by comprising oligosaccharides selected from the group consisting of fructo-oligosaccharides, malto-oligosaccharides, isomalto-oligosaccharides, galacto-oligosaccharides, soybean oligosaccharides and combinations thereof.
前記プレバイオティクス組成物はチコリ抽出物、デキストリン、精製水及びこれらの組み合わせからなる群から選択される物質を更に含むことを特徴とするものであってよい。 The prebiotic composition may further comprise a substance selected from the group consisting of chicory extract, dextrin, purified water and combinations thereof.
又、本発明の他の一側面は、
前記食物繊維が豊富なプレバイオティクス組成物及び乳酸菌の菌株を含むことを特徴とする食物繊維が豊富なプロバイオティクス組成物を提供する。
Another aspect of the present invention is
Provided is a probiotic composition rich in dietary fiber characterized by comprising the prebiotic composition rich in dietary fiber and a strain of lactic acid bacteria.
前記乳酸菌の菌株はラクトバチルス(Lactobacillus)、ストレプトコッカスサーモフィルス(Streptococcus thermophilus)、ビフィズス菌(ビフィドバクテリウム、Bifidobacterium)、複合乳酸菌ABT-B菌株及びこれらの組み合わせからなる群から選択される乳酸菌の菌株を含むことを特徴とするものであってよい。 The lactic acid bacterium strain is a lactic acid bacterium strain selected from the group consisting of Lactobacillus, Streptococcus thermophilus, Bifidobacterium, complex lactic acid bacterium ABT-B strain and combinations thereof. It may be characterized by including
又、本発明のまた他の一側面は、
キノコ及び精製水の混合物を抽出器に投入させて80℃乃至120℃の温度で1次抽出させる段階;前記1次抽出させた混合物を60℃乃至100℃の温度で2次抽出させる段階;前記2次抽出させた混合物を40℃乃至80℃の温度で3次抽出させてキノコ抽出物を製造する段階;及び前記製造されたキノコ抽出物に原乳、粉乳、糖及びこれらの組み合わせからなる群から選択される物質を含む添加剤を混合した後均質化してプレバイオティクス組成物を製造する段階;を含むことを特徴とする食物繊維が豊富なプレバイオティクス組成物の製造方法を提供する。
In addition, another aspect of the present invention is
introducing a mixture of mushrooms and purified water into an extractor for primary extraction at a temperature of 80 to 120°C; secondary extraction of the primary extracted mixture at a temperature of 60 to 100°C; tertiary extraction of the second-extracted mixture at a temperature of 40° C. to 80° C. to prepare a mushroom extract; mixing and then homogenizing an additive containing a substance selected from to produce a prebiotic composition to produce a prebiotic composition rich in dietary fiber.
前記キノコ抽出物はマンネンタケ抽出物を含むことを特徴とするものであってよい。 The mushroom extract may be characterized by comprising a Ganoderma lucidum extract.
前記プレバイオティクス組成物は前記キノコ抽出物100重量部対比食物繊維の含量が30重量部以上であることを特徴とするものであってよい。 The prebiotic composition may contain 30 parts by weight or more of dietary fiber for 100 parts by weight of the mushroom extract.
又、本発明の最後の他の一側面は、
前記製造したプレバイオティクス組成物に乳酸菌の菌株を接種させる段階;及び前記接種された乳酸菌の菌株を培養させる段階;を含むことを特徴とする食物繊維が豊富なプロバイオティクス組成物の製造方法を提供する。
Also, the last other aspect of the present invention is
A method for producing a probiotic composition rich in dietary fiber, comprising the steps of: inoculating the produced prebiotic composition with a strain of lactic acid bacteria; and culturing the inoculated strain of lactic acid bacteria. I will provide a.
本発明に従う、プレバイオティクス組成物は3次抽出したキノコ抽出物を含むことで豊富な食物繊維を有するものであることができる。又、前記キノコ抽出物に含まれた食物繊維は不溶性食物繊維だけではなく生理活性機能を持つ水溶性食物繊維を多量含有するものであることができる。従って、前記プレバイオティクス組成物を摂取する場合、豊富な食物繊維によって便通を大きく向上させる効果を有するものであることができる。 A prebiotic composition according to the present invention can be rich in dietary fiber by including a tertiary extracted mushroom extract. Also, the dietary fiber contained in the mushroom extract may contain a large amount of not only insoluble dietary fiber but also water-soluble dietary fiber having physiologically active functions. Therefore, when the prebiotic composition is ingested, it may have the effect of greatly improving bowel movements due to its rich dietary fiber.
又、前記プレバイオティクス組成物に乳酸菌の菌株を接種して培養する場合、より優れた乳酸菌増殖率を表するものであることができる。これに従って前記プレバイオティクス組成物に乳酸菌の菌株を接種して培養したプロバイオティクス組成物は豊富な乳酸菌の菌株を保有するものであることができる。従って、前記プロバイオティクス組成物は乳酸菌の整腸作用及び免疫力向上等の効能だけではなく食物繊維による血糖上昇抑制及び血中コレストロール数値降下効果等抗肥満効果を表するものであることができる。 In addition, when the prebiotic composition is inoculated with a lactic acid bacterium strain and cultured, it may exhibit a better lactic acid bacterium growth rate. According to this, the probiotic composition obtained by inoculating and culturing the prebiotic composition with a lactic acid bacterium strain can contain abundant lactic acid bacterium strains. Therefore, the probiotic composition can exhibit not only the effect of lactic acid bacteria for regulating the intestines and improving immunity, but also the anti-obesity effect such as the suppression of blood sugar elevation and blood cholesterol level lowering effect due to dietary fiber. .
図1は本発明の一具現例に従ったプレバイオティクス組成物の製造方法を概略的に表したフローチャートである。 FIG. 1 is a flow chart that schematically illustrates a method for producing a prebiotic composition according to one embodiment of the present invention.
図2は本発明の一具現例に従ったプロバイオティクス組成物の製造方法を概略的に表したフローチャートである。 FIG. 2 is a flow chart that schematically illustrates a method for producing a probiotic composition according to one embodiment of the present invention.
図3a及び3bは一般的な食品に含有されている食物繊維の含量を表したグラフである。 3a and 3b are graphs showing the content of dietary fiber contained in common foods.
図4は本発明の一実施例及び比較例に従って製造されたヨーグルトの抗肥満効果を表したグラフである。 FIG. 4 is a graph showing the anti-obesity effect of yogurt produced according to an example and a comparative example of the present invention.
図5a及び5bはそれぞれ本発明の一実施例及び比較例に従って製造されたヨーグルトの中性脂肪含量減少効果及び総コレストロール含量減少効果を表したグラフである。 Figures 5a and 5b are graphs showing the effect of reducing triglyceride content and total cholesterol content of yogurt prepared according to an example and a comparative example of the present invention, respectively.
以下、本発明が属する技術分野で通常の知識を有する者が容易に実施できるように本発明の実施例に対して詳細に説明する。しかし、本発明は色んな相異なる形態に具現できるしここで説明する実施例に限定されない。 Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.
実施例.プロバイオティクス組成物を含むヨーグルトの製造
1.キノコ抽出物の製造
キノコ抽出物を製造するため、先ず、マンネンタケ、椎茸及びエリンギを0.02:0.2:2の重量比率で精製水と混合した後、抽出器に入れて100℃の温度で2時間の間加熱させて1次抽出を行った。以後、1次抽出を行った前記混合物を常温で1時間くらい放冷させた後、また80℃の温度で2時間の間加熱させて2次抽出を行った。その後、2次抽出を行った前記混合物を常温で1時間くらい放冷させた後、最後に60℃の温度で2時間の間加熱させて3次抽出を行った。以後、前記3次抽出を行った前記混合物を常温で15時間くらい放冷させてキノコ抽出物を製造した。
Example. Manufacture of yogurt containing probiotic composition
1. Preparation of Mushroom Extract To prepare mushroom extract, Ganoderma lucidum, shiitake mushroom and king oyster mushroom were first mixed with purified water in a weight ratio of 0.02:0.2:2, and then placed in an extractor at a temperature of 100°C. was heated for 2 hours to perform primary extraction. After the first extraction, the mixture was allowed to cool at room temperature for about 1 hour, and then heated at 80° C. for 2 hours to perform the second extraction. After the second extraction, the mixture was allowed to cool at room temperature for about 1 hour, and finally heated at 60° C. for 2 hours to perform the third extraction. After that, the mixture subjected to the tertiary extraction was left to cool at room temperature for about 15 hours to prepare a mushroom extract.
2.プレバイオティクス組成物の製造
前記1.で製造したキノコ抽出物82.965gに脱脂粉乳10g、フラクトオリゴ糖3g、デキストリン2g及びチコリ抽出物粉末2gを混合して、これを均質化してプレバイオティクス組成物を製造した。以後、前記製造したプレバイオティクス組成物を100℃の温度で1時間の間加熱して滅菌処理を行った後、これを36℃乃至40℃の温度に冷却させた。
2. Manufacture of
3.プロバイオティクス組成物を含むヨーグルトの製造
前記2.で製造したプレバイオティクス組成物99.965gに複合乳酸菌ABT-B菌株0.035gを接種し、これを恒温培養器で約5時間乃至8時間の間発酵させた後、5℃以下の温度で熟成させてプロバイオティクス組成物を含むヨーグルトを製造した。
3. Production of yogurt containing
比較例1.キノコ抽出物の製造
比較例に従ったキノコ抽出物を製造するためマンネンタケ、椎茸及びエリンギを0.02:0.2:2の重量比率で精製水と混合した後、抽出器に入れて100℃の温度で2時間の間加熱させて抽出を行った。以後、前記抽出を行った前記混合物を常温で15時間くらい放冷させてキノコ抽出物を製造した。
Comparative example 1. Preparation of Mushroom Extract According to Comparative Example To prepare mushroom extract, Ganoderma lucidum, shiitake mushroom and king oyster mushroom were mixed with purified water in a weight ratio of 0.02:0.2:2, and then placed in an extractor at 100°C. The extraction was performed by heating for 2 hours at a temperature of . After that, the extracted mixture was allowed to cool at room temperature for about 15 hours to prepare a mushroom extract.
比較例2.一般的なヨーグルトの製造
比較例に従った一般的なヨーグルトを製造するため、先ず、原乳と砂糖を混合してこれを均質化させて乳酸その菌培地組成物を製造したし、これを100℃の温度で1時間の間加熱して滅菌処理を行った後、これを36℃乃至40℃の温度で冷却させた。その後、前記乳酸菌培地組成物99.965gに複合乳酸菌ABT-B菌株0.035gを接種して、これを恒温培養器で約5時間乃至8時間の間発酵させた後、5℃以下の温度で熟成させて一般的なヨーグルトを製造した。
Comparative example 2. In order to manufacture a common yogurt according to the Comparative Example for the Production of Common Yogurt, first, raw milk and sugar were mixed and homogenized to produce a lactobacillus culture medium composition. C. for 1 hour for sterilization, and then cooled at a temperature of 36.degree. C. to 40.degree. After that, 0.035 g of the complex lactic acid bacterium ABT-B strain was inoculated into 99.965 g of the lactic acid bacteria medium composition, and fermented in a constant temperature incubator for about 5 to 8 hours, and then at a temperature of 5 ° C. or less. It was aged to produce common yoghurt.
実験例1.キノコ抽出物の食物繊維含有量測定
前記実施例の1.で製造したキノコ抽出物及び比較例1に従ったキノコ抽出物の含有された食物繊維の含量を測定したし、これの結果を下記表1に表した。
Experimental example 1. Measurement of dietary fiber content of mushroom extract The dietary fiber content of the mushroom extract prepared in Example 1 and the mushroom extract according to Comparative Example 1 was measured, and the results are shown in Table 1 below.
前記表1に表した通り、本発明の実施例に従って3次抽出を行ったキノコ抽出物が比較例1の1次抽出だけを行ったキノコ抽出物に比べて桁外れに高い食物繊維含有量を持つことを確認できた。これを通じて、実施例に従って製造したキノコ抽出物は同一な量で摂取量を増大させることで糖分の吸収を遅くして血糖の急激な上昇を抑制し、胃と大腸を通過する時、水分と一緒に腸内脂肪を吸着して排出させる作用をするため便通効果を大きく向上させられることを確認できた。 As shown in Table 1, the mushroom extract subjected to the third extraction according to the example of the present invention has an extremely high dietary fiber content compared to the mushroom extract subjected to the first extraction of Comparative Example 1. I was able to confirm that. Through this, the mushroom extract prepared according to the example was increased in intake with the same amount, slowing the absorption of sugar and suppressing the rapid rise of blood sugar, and when passing through the stomach and large intestine, it was mixed with water. It was confirmed that the defecation effect can be greatly improved because it acts to adsorb and excrete intestinal fat.
実験例2.乳酸菌増殖率測定
前記実施例の2.で製造したプレバイオティクス組成物と比較例2に従った乳酸菌培地組成物の乳酸菌増殖程度を確認するため、前記実施例及び比較例2に従った組成物をそれぞれ100μLずつ取って希釈液で希釈させた後、Petri dishに1mLの希釈液を入れた後Pouring法によってWater bathにあるBCP培地に塗抹した。以後、これをIncubatorで37℃の温度で72時間乃至84時間の間培養させた後、現れたcolonyの個数を確認して希釈倍数を掛けた生菌数を計算してその結果を下記表2に表した。
Experimental example 2. Lactic acid bacteria
前記表2に表した通り、本発明の実施例に従って製造したプレバイオティクス組成物は比較例2に従った乳酸菌培地組成物に比べて桁外れに高い乳酸菌増殖率を持つことを確認できた。 As shown in Table 2, it was confirmed that the prebiotic composition prepared according to the example of the present invention has an extremely high growth rate of lactic acid bacteria compared to the lactic acid bacteria culture medium composition according to Comparative Example 2.
実験例3.抗肥満効果測定
前記実施例で製造したヨーグルトのコレストロール及び脂肪蓄積阻害に及ぼす影響を実験動物を利用して検討した。実験動物であるネズミ(rat)は4週齡を購入して使用したし正常食餌群(normal feeding control rat、NC)、高脂肪食餌対照群(high fat feeding control rat、HC)、低濃度ヨーグルト投与高脂肪食餌群(high fat rat with yogurt、HM)及び高濃度ヨーグルト投与高脂肪食餌群(high fat rat with large yogurt、HH)に分けて飼育したし、この体重変化量を測定してその結果を図4に表した。
Experimental example 3. Measurement of anti-obesity effect The effect of the yogurt produced in the above example on inhibition of cholesterol and fat accumulation was examined using experimental animals. Experimental animals (rat) were purchased and used at 4 weeks of age, normal feeding control rats (NC), high fat feeding control rats (HC), and low-concentration yoghurt administration. A high fat diet group (high fat rat with yogurt, HM) and a high fat diet administration group of high-concentration yogurt (high fat rat with large yogurt, HH) were bred separately, and the weight change was measured and the results were obtained. It is shown in FIG.
その結果、図4に表した通り、高脂肪食餌摂取で肥満を誘導した高脂肪食餌対照群の体重増加量が75gであることに反して、低濃度ヨーグルト投与した高脂肪食餌群(HM)の体重増加量は59gで高脂肪食餌対照群対比21.3%肥満抑制効果を見せたし、なおかつ高濃度ヨーグルト投与高脂肪食餌群(HH)は高脂肪食餌対照群対比体重減少量が45gで60%の肥満抑制効果を表すことを確認できた。 As a result, as shown in FIG. 4, the weight gain of the high-fat diet control group, in which obesity was induced by high-fat diet intake, was 75 g. The weight gain was 59g, showing an obesity suppression effect of 21.3% compared to the high-fat diet control group. % obesity inhibitory effect.
又、前記ネズミの血清中の中性脂肪含量変化量及び総コレストロール含量変化量を測定したし、その結果を図5a及び5bにそれぞれ表した。 In addition, changes in triglyceride content and total cholesterol content in the serum of the rats were measured, and the results are shown in Figures 5a and 5b, respectively.
先ず、図5aに表した通り、高脂肪食餌誘導肥満ネズミにヨーグルトを投与する場合、血清の中性脂肪の含量を減少させたし中性脂肪含量は高脂肪食餌対照群に比べて36%の顕著な低下を見せた。 First, as shown in Fig. 5a, administration of yogurt to high-fat diet-induced obese rats decreased serum triglyceride content, and triglyceride content decreased by 36% compared to the high-fat diet control group. showed a marked decline.
又、図5bに表した通り、血清中の総コレストロール含量は正常食餌を給与した正常群に比べて高脂肪食餌対照群で差がないがHMとHHのヨーグルト投与群では有意的に総コレストロール含量が減少してHHのヨーグルト投与群は実験群に比べて37%が減少することを分かることができた。 In addition, as shown in Fig. 5b, there was no difference in the serum total cholesterol content between the high-fat diet control group and the normal diet-fed normal group, but the total cholesterol content in the HM and HH yogurt-administered groups was significantly higher. It was found that the HH yogurt-administered group decreased by 37% compared to the experimental group.
以上、図面を参照して好ましい実施例と一緒に本発明に対して詳細に説明したが、このような図面と実施例で本発明の技術的思想の範囲が限定されるのではない。従って、本発明の技術的思想の範囲内で多様な変形例又は均等な範囲の実施例が存在できる。従って本発明に従う、技術的思想の権利範囲は請求範囲によって解釈されるべきであり、これと同等であったり、均等な範囲内の技術思想は本発明の権利範囲に属するものと解釈されるべきである。 Although the present invention has been described in detail along with preferred embodiments with reference to the drawings, the scope of the technical idea of the present invention is not limited to such drawings and embodiments. Therefore, various modifications or equivalent embodiments can exist within the scope of the technical idea of the present invention. Therefore, the scope of rights of the technical ideas according to the present invention should be construed according to the claims, and technical ideas equivalent to or within the equivalent range should be construed as belonging to the scope of rights of the present invention. is.
後述する本発明に対する説明は、本発明が実施できる特定実施例を例示として参照する。これら実施例は当業者が本発明を実施するのに十分であるように詳細に説明される。本発明の多様な実施例は互いに違うが相互排除的である必要はないことが理解されるべきである。例えば、ここに記載されている特定形象、構造及び特性は一実施例に関して本発明の技術的思想及び範囲を外れないながら他の実施例で具現できる。又、それぞれの開示された実施例内の個別構成要素の位置又は配置は本発明の技術的思想及び範囲を外れないながら変更できることが理解されるべきである。 The following description of the invention refers, by way of illustration, to specific embodiments in which the invention can be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention. It should be understood that various embodiments of the invention are different from one another and need not be mutually exclusive. For example, the specific features, structures and characteristics described herein with respect to one embodiment can be implemented in other embodiments without departing from the spirit and scope of the invention. Also, it should be understood that the position or arrangement of individual components within each disclosed embodiment may be changed without departing from the spirit and scope of the present invention.
従って、後述する詳細な説明は限定的な意味として取ろうとするのではないし、本発明の範囲は、適切に説明されるなら、その請求項たちが主張するのと均等な全ての範囲と一緒に添付された請求項によりだけ限定される。 Therefore, the following detailed description is not to be taken in a limiting sense, and the scope of the invention, if properly set forth, is intended to be, along with the full range of equivalents claimed by the claims. limited only by the appended claims.
以下、本発明が属する技術分野で通常の知識を有する者が本発明を容易に実施できるようにするために、本発明の好ましい実施例たちに関して参照して詳細に説明することにする。 Hereinafter, preferred embodiments of the present invention will be referred to and described in detail so that those skilled in the art to which the present invention pertains can easily implement the present invention.
本願の第1側面は、
キノコ抽出物及び添加剤を含むプレバイオティクス組成物として、前記キノコ抽出物はマンネンタケ抽出物を含むことであり、前記添加剤は原乳、粉乳、糖及びこれらの組み合わせからなる群から選択される物質を含むことであり、前記プレバイオティクス組成物は前記キノコ抽出物100重量部対比食物繊維の含量が30重量部以上であることを特徴とする食物繊維が豊富なプレバイオティクス組成物を提供する。
A first aspect of the present application is
A prebiotic composition comprising a mushroom extract and an additive, wherein the mushroom extract comprises a Ganoderma lucidum extract, and the additive is selected from the group consisting of raw milk, powdered milk, sugar and combinations thereof. A prebiotic composition rich in dietary fiber, wherein the prebiotic composition contains 30 parts by weight or more of dietary fiber relative to 100 parts by weight of the mushroom extract. do.
本願の第2側面は、
前記本願の第1側面に従った食物繊維が豊富なプレバイオティクス組成物及び乳酸菌の菌株を含むことを特徴とする食物繊維が豊富なプロバイオティクス組成物を提供する。
A second aspect of the present application is
There is provided a dietary fiber-rich prebiotic composition according to the first aspect of the present application and a dietary fiber-rich probiotic composition comprising a strain of lactic acid bacteria.
以下、本願の第1側面に従った食物繊維が豊富なプレバイオティクス組成物及び本願の第2側面に従った食物繊維が豊富なプロバイオティクス組成物を詳細に説明することにする。 The dietary fiber-rich prebiotic composition according to the first aspect of the present application and the dietary fiber-rich probiotic composition according to the second aspect of the present application will now be described in detail.
本願の一具現例にあって、前記プレバイオティクス組成物はキノコ抽出物を含むものであることができる。一般的に味が良い食用キノコにはアミノ酸、マンニット、トレハロース等がたくさんあるし、その他にビタミンB2とビタミンDの前駆体であるエルゴステリンのような色んなビタミン類と酵素も入っていると知られている。又、最近キノコは抗癌効果、抗変異原性効果、血清脂質低下効果、免疫増強効果等老化抑制及び成人病予防と治療に効験があると知られながら食用だけではなく薬用でもその利用性が日々増大しているが、このような生理活性が期待されるキノコ類にはマンネンタケ、椎茸、エリンギ、メシマコブ、アガリクス(ヒラタケ)、ササクレヒトヨタケ(Coprinus)、キクラゲ(Auricularia auricula-judae)、ツリガネタケ(ホクチタケ、Fomes fomentarius)及びイワタケ(Umbilicaria esculenta)等の食用及び薬用キノコ類が知られている。 In one embodiment of the present application, the prebiotic composition may contain mushroom extract. In general, edible mushrooms with good taste are rich in amino acids, mannite, trehalose, etc., and are known to contain various vitamins and enzymes such as ergosterin, a precursor of vitamin B2 and vitamin D. ing. Recently, mushrooms have been known to have anti-cancer effects, anti-mutagenic effects, serum lipid-lowering effects, immune-enhancing effects, etc., as well as anti-aging effects and prevention and treatment of geriatric diseases. Mushrooms expected to have such physiological activity include Ganoderma lucidum, shiitake mushroom, eryngii mushroom, mushroom mushroom, agaricus (Oyster mushroom), coprinus (Coprinus), wood ear mushroom (Auricularia auricula-judae), and vortices ( Edible and medicinal mushrooms such as Hokchitake (Fomes fomentarius) and Rock Mushroom (Umbilicaria esculenta) are known.
特に、マンネンタケの薬効成分で熱水抽出液に含有されている多糖類とたんぱく質複合体であるpolysaccharide protein complexが報告されたことがあり、癌細胞生育抑制、本態性高血圧治療、過酸化脂質生成抑制効果等が報告されたことがある。食用で広く利用されている椎茸には抗癌作用、コレストロール低下作用、強壮、利尿、高血圧、腎臓炎、喘息、胃潰瘍等の治療にも効能があって薬用としても広く利用されているし、椎茸熱水抽出物は血清及び肝臓の脂質低下作用及び肝損傷抑制作用が報告されたことがある。又、エリンギの多糖類抽出物は血清コレストロール低下効果及び四塩化炭素誘発肝損傷抑制作用とエリンギ子実体及び菌糸体抽出物の抗酸化効果があることと報告されたことがある。 In particular, polysaccharide protein complex, which is a polysaccharide and protein complex contained in hot water extract, has been reported as a medicinal ingredient of Ganoderma lucidum, and has been reported to inhibit cancer cell growth, treat essential hypertension, and inhibit lipid peroxide production. There have been reports of effects, etc. Shiitake mushrooms, which are widely used as food, have anticancer effects, cholesterol-lowering effects, tonic, diuretic, hypertension, nephritis, asthma, gastric ulcer, etc., and are also widely used for medicinal purposes. The hot water extract has been reported to have serum and liver lipid-lowering effects and liver injury-inhibitory effects. In addition, it has been reported that eryngii polysaccharide extract has serum cholesterol-lowering effect and carbon tetrachloride-induced liver injury inhibitory effect, and eryngii fruiting body and mycelium extract have antioxidant effect.
本願の一具現例にあって、前記キノコ抽出物はマンネンタケ抽出物を含むことがあり、前記抽出物に使用されるマンネンタケは図3a及び3bに表した通り、他のキノコや食品に比べて高い総食物繊維含有量を持つのでこれを含む前記プレバイオティクス組成物が豊富な食物繊維含有量を有するものであることができる。一方、前記マンネンタケは不溶性食物繊維に比べて桁外れに高い水溶性食物繊維含有量を持つので高い生理活性を有するものであることができる。 In one embodiment of the present application, the mushroom extract may include Ganoderma lucidum extract, and Ganoderma lucidum used for the extract is more expensive than other mushrooms and foods, as shown in FIGS. 3a and 3b. Having a total dietary fiber content, the prebiotic composition comprising it can have a rich dietary fiber content. On the other hand, since the Ganoderma lucidum has much higher water-soluble dietary fiber content than insoluble dietary fiber, it may have high bioactivity.
本願の一具現例にあって、前記キノコ抽出物は前記マンネンタケ抽出物以外に、椎茸、エリンギ、エノキタケ、ヒラタケ、マッシュルーム、メシマコブ、ブナシメジ、ハナビラタケ、カバノアナタケ、ヤマブシタケ及びこれらの組み合わせからなる群から選択されるキノコの抽出物を更に含むことがあり、好ましく椎茸及びエリンギの抽出物を更に含むものであることができる。即ち、本願の一実施例によると前記プレバイオティクス組成物に含まれるキノコ抽出物はマンネンタケ抽出物、椎茸抽出物及びエリンギ抽出物であることができる。この場合、前記マンネンタケ抽出物1重量部対比前記椎茸抽出物の含量は5重量部乃至20重量部でありうるし、前記エリンギ抽出物の含量は50重量部乃至200重量部であるものであることができる。好ましく本願の一実施例に従うと前記マンネンタケ抽出物1重量部対比前記椎茸抽出物の含量は10重量部であり、前記エリンギ抽出物の含量は100重量部であるものであることができる。 In one embodiment of the present application, the mushroom extract, in addition to the Ganoderma lucidum extract, is selected from the group consisting of shiitake mushrooms, eryngii, enokitake, oyster mushrooms, mushrooms, Korean mushrooms, bunashimeji mushrooms, sparassis crispa, birch anatake, ericaceae, and combinations thereof. It may further contain an extract of a mushroom, preferably an extract of shiitake mushroom and king oyster mushroom. That is, according to an embodiment of the present application, the mushroom extract contained in the prebiotic composition may be Ganoderma lucidum extract, shiitake mushroom extract and king oyster mushroom extract. In this case, the content of the shiitake mushroom extract may be 5 to 20 parts by weight, and the content of the king oyster mushroom extract may be 50 to 200 parts by weight, relative to 1 part by weight of the Ganoderma lucidum extract. can. Preferably, according to one embodiment of the present application, the content of the shiitake mushroom extract may be 10 parts by weight, and the content of the king oyster mushroom extract may be 100 parts by weight, based on 1 part by weight of the Ganoderma lucidum extract.
本願の一具現例にあって、前記キノコ抽出物は子実体又は菌糸体の抽出物でありうるし、好ましくは子実体抽出物を使用するものであることができる。 In one embodiment of the present application, the mushroom extract may be a fruiting body or mycelium extract, and preferably a fruiting body extract.
本願の一具現例にあって、前記プレバイオティクス組成物は添加剤を含むものであることができる。この時、前記添加剤は原乳、粉乳、糖及びこれらの組み合わせからなる群から選択される物質を含むものであることができる。一方、前記添加剤は前記キノコ抽出物と混合されて、均質化されることで乳酸菌培養組成物、即ちプレバイオティクス組成物を成すものであることができる。この時、前記キノコ抽出物の含量は前記添加剤100重量部対比400重量部乃至600重量部でありうるし、好ましく400重量部乃至500重量部でありうるし、より好ましくは450重量部乃至500重量部であるものであることができる。一方、前記キノコ抽出物の含量が前記添加剤100重量部対比400重量部未満である場合前記キノコ抽出物の含量が相対的に少なくてこれを含むプレバイオティクス組成物が食物繊維を少なく含有できるし、600重量部超過である場合前記添加剤の含量が相対的に少なく、追って乳酸菌培養に難しさが発生することがある。本願の一実施例に従うと前記キノコ抽出物の含量は前記添加剤100重量部対比約487重量部であるものであることができる。 In one embodiment of the present application, the prebiotic composition may contain additives. At this time, the additive may include a material selected from the group consisting of raw milk, powdered milk, sugar and combinations thereof. Meanwhile, the additive can be mixed with the mushroom extract and homogenized to form a lactic acid bacteria culture composition, ie, a prebiotic composition. At this time, the content of the mushroom extract may be 400 to 600 parts by weight, preferably 400 to 500 parts by weight, more preferably 450 to 500 parts by weight, based on 100 parts by weight of the additive. can be what is On the other hand, when the content of the mushroom extract is less than 400 parts by weight based on 100 parts by weight of the additive, the content of the mushroom extract is relatively low, and the prebiotic composition containing the mushroom extract may contain less dietary fiber. However, if it exceeds 600 parts by weight, the content of the additive is relatively small, which may cause difficulty in culturing lactic acid bacteria. According to one embodiment of the present application, the content of the mushroom extract may be about 487 parts by weight based on 100 parts by weight of the additive.
本願の一具現例にあって、前記粉乳は全脂粉乳及び/又は脱脂粉乳を使用することがあり、好ましくは脱脂粉乳を使用するものであることができる。一方、前記粉乳の他にも原乳が混用可能なことでありうるし、これは製造しようとするプレバイオティクス組成物の特性に合うように使用者が適切に選択して使用するものであることができる。この時、前記原乳又は粉乳の含量は前記キノコ抽出物100重量部対比5重量部乃至20重量部でありうるし、好ましく10重量部乃至15重量部でありうるし、本願の一実施例に従うと約12重量部であるものであることができる。前記原乳又は粉乳の含量が前記範囲を逃れる場合前記添加剤の適正含量範囲を逃れる場合と同一な問題が発生することがある。 In an embodiment of the present application, the milk powder may be whole milk powder and/or skim milk powder, preferably skim milk powder. On the other hand, raw milk may be used in addition to the powdered milk, and it should be appropriately selected and used by the user according to the characteristics of the prebiotic composition to be manufactured. can be done. At this time, the content of the raw milk or powdered milk may be 5 to 20 parts by weight, preferably 10 to 15 parts by weight, based on 100 parts by weight of the mushroom extract. 12 parts by weight. When the content of the raw milk or powdered milk is out of the range, the same problem may occur as when the additive content is out of the appropriate range.
本願の一具現例にあって、前記糖は単糖類、二糖類、糖アルコール類、オリゴ糖類、デキストリン及びこれらの組み合わせからなる群から選択される糖を含むことでありうるし、好ましくオリゴ糖類を含むものであることができる。一方、前記糖がオリゴ糖類を含む場合、前記オリゴ糖類はフラクトオリゴ糖、マルトオリゴ糖、イソマルトオリゴ糖、ガラクトオリゴ糖、大豆オリゴ糖及びこれらの組み合わせからなる群から選択されるオリゴ糖を含むことがあり、好ましくフラクトオリゴ糖を含むものであることができる。一方、前記糖の含量は前記キノコ抽出物100重量部対比1重量部乃至5重量部でありうるし、本願の一実施例に従うと約3.6重量部であるものであることができる。前記糖の含量が前記範囲を逃れる場合同様に前記添加剤の適正含量範囲を逃れる場合と同一な問題が発生することがある。 In one embodiment of the present application, the sugars may include sugars selected from the group consisting of monosaccharides, disaccharides, sugar alcohols, oligosaccharides, dextrins and combinations thereof, preferably oligosaccharides. It can be On the other hand, when the sugar contains an oligosaccharide, the oligosaccharide may contain an oligosaccharide selected from the group consisting of fructo-oligosaccharide, malto-oligosaccharide, isomalto-oligosaccharide, galacto-oligosaccharide, soybean oligosaccharide and combinations thereof, It can preferably contain fructooligosaccharides. Meanwhile, the content of the sugar may be 1 to 5 parts by weight based on 100 parts by weight of the mushroom extract, and may be about 3.6 parts by weight according to an embodiment of the present application. When the content of sugar is out of the range, the same problem may occur as when the content of the additive is out of the proper range.
本願の一具現例にあって、前記プレバイオティクス組成物は前記物質たちの他にチコリ抽出物、デキストリン、精製水及びこれらの組み合わせからなる群から選択される物質を更に含むものであることができる。この時、前記チコリ抽出物及びデキストリンの含量は前記キノコ抽出物100重量部対比1重量部乃至5重量部でありうるし、本願の一実施例に従うと約2.4重量部であるものであることができる。 In one embodiment of the present application, the prebiotic composition may further include a substance selected from the group consisting of chicory extract, dextrin, purified water, and combinations thereof, in addition to the above substances. At this time, the content of the chicory extract and dextrin may be 1 to 5 parts by weight, or about 2.4 parts by weight according to an embodiment of the present application, based on 100 parts by weight of the mushroom extract. can be done.
本願の一具現例にあって、前記プレバイオティクス組成物はキノコ抽出物を含むことで高い食物繊維含有量を持つことがあり、この時前記食物繊維の含量はキノコ抽出物100重量部対比30重量部以上でありうるし、好ましくは60重量部乃至80重量部でありうるし、本願の一実施例に従うと約67.16重量部であるものであることができる。即ち、前記プレバイオティクスの高い食物繊維含有量は前記キノコ抽出物がマンネンタケ抽出物を含むためでありうるし、前記キノコ抽出物を3次抽出して製造することで達成可能なものであることができる。 In one embodiment of the present application, the prebiotic composition may contain a mushroom extract to have a high dietary fiber content, wherein the dietary fiber content is 30 parts per 100 parts by weight of the mushroom extract. Part by weight or more, preferably 60 to 80 parts by weight, and according to one embodiment of the present application, may be about 67.16 parts by weight. That is, the high dietary fiber content of the prebiotics may be due to the fact that the mushroom extract contains the Ganoderma lucidum extract, and it can be achieved by tertiary extraction of the mushroom extract. can.
本願の一具現例にあって、前記食物繊維は水溶性食物繊維及び不溶性食物繊維を含むことでありうるし、この時、前記食物繊維全体100重量部対比前記水溶性食物繊維の含量は40重量部乃至80重量部であり、前記不溶性食物繊維の含量は20重量部乃至60重量部であるものであることができる。即ち、一般的に市中に流通されるプレバイオティクス組成物の場合食物繊維全体100重量部対比前記水溶性食物繊維の含量が約20重量部であり、不溶性食物繊維の含量が約80重量部である反面、本発明に従う、プレバイオティクス組成物の場合前記のように高い水溶性食物繊維の含量を持つため生理活性機能が優秀なものであることができる。従って、前記プレバイオティクス組成物を摂取する場合、豊富な食物繊維によって便通が大きく向上される効果を有するものであることができる。この時、好ましく前記食物繊維全体100重量部対比前記水溶性食物繊維の含量は約60重量部であり、前記不溶性食物繊維の含量は約40重量部であるものであることができる。 In one embodiment of the present application, the dietary fiber may include soluble dietary fiber and insoluble dietary fiber, and the content of the soluble dietary fiber is 40 parts by weight based on 100 parts by weight of the total dietary fiber. 80 parts by weight, and the content of the insoluble dietary fiber may be 20 parts by weight to 60 parts by weight. That is, the prebiotic composition generally distributed in the market contains about 20 parts by weight of the water-soluble dietary fiber and about 80 parts by weight of the insoluble dietary fiber relative to 100 parts by weight of the total dietary fiber. On the other hand, the prebiotic composition according to the present invention has a high content of water-soluble dietary fiber as described above, so that the bioactive function can be excellent. Therefore, when the prebiotic composition is ingested, it may have the effect of greatly improving bowel movements due to its rich dietary fiber. At this time, the content of the water-soluble dietary fiber is preferably about 60 parts by weight, and the content of the insoluble dietary fiber is about 40 parts by weight, based on 100 parts by weight of the total dietary fiber.
本願の一具現例にあって、前記プロバイオティクス組成物は前記したプレバイオティクス組成物及び乳酸菌の菌株を含むものであることができる。この時、前記プレバイオティクス組成物は優秀な乳酸菌の菌株の増殖能力を有するものでありうるし、これに従って前記プロバイオティクス組成物は豊富な乳酸菌の菌株を保有するものであることができる。従って、前記プロバイオティクス組成物は乳酸菌の整腸作用及び免疫力向上等の効能だけではなく食物繊維による血糖上昇抑制及び血中コレストロール数値降下効果等抗肥満効果を表するものであることができる。 In one embodiment of the present application, the probiotic composition may comprise the prebiotic composition described above and a strain of lactic acid bacteria. At this time, the prebiotic composition may have an excellent lactic acid bacterium strain growth ability, and thus the probiotic composition may have an abundant lactic acid bacterium strain. Therefore, the probiotic composition can exhibit not only the effect of lactic acid bacteria for regulating the intestines and improving immunity, but also the anti-obesity effect such as the suppression of blood sugar elevation and blood cholesterol level lowering effect due to dietary fiber. .
本願の一具現例にあって、前記乳酸菌の菌株はラクトバチルス(Lactobacillus)、ストレプトコッカスサーモフィルス(Streptococcus thermophilus)、ビフィズス菌(Bifidobacterium)、複合乳酸菌ABT-B菌株及びこれらの組み合わせからなる群から選択される乳酸菌の菌株を含むことがあり、本願の一実施例に従うと前記乳酸菌の菌株は複合乳酸菌ABT-B菌株であるものであることができる。 In one embodiment of the present application, the strain of lactic acid bacteria is selected from the group consisting of Lactobacillus, Streptococcus thermophilus, Bifidobacterium, ABT-B complex lactic acid bacteria strain, and combinations thereof. and according to one embodiment of the present application, the lactic acid bacterium strain may be a complex lactic acid bacterium ABT-B strain.
本願の第3側面は、
キノコ及び精製水の混合物を抽出器に投入させて80℃乃至120℃の温度で1次抽出させる段階;前記1次抽出させた混合物を60℃乃至100℃の温度で2次抽出させる段階;前記2次抽出させた混合物を40℃乃至80℃の温度で3次抽出させてキノコ抽出物を製造する段階;及び前記製造されたキノコ抽出物に原乳、粉乳、糖及びこれらの組み合わせからなる群から選択される物質を含む添加剤を混合した後均質化してプレバイオティクス組成物を製造する段階;を含むことを特徴とする食物繊維が豊富なプレバイオティクス組成物の製造方法を提供する。
A third aspect of the present application is
introducing a mixture of mushrooms and purified water into an extractor for primary extraction at a temperature of 80 to 120°C; secondary extraction of the primary extracted mixture at a temperature of 60 to 100°C; tertiary extraction of the second-extracted mixture at a temperature of 40° C. to 80° C. to prepare a mushroom extract; mixing and then homogenizing an additive containing a substance selected from to produce a prebiotic composition to produce a prebiotic composition rich in dietary fiber.
本願の第4側面は、
前記本願の第3側面で製造したプレバイオティクス組成物に乳酸菌の菌株を接種させる段階;及び前記接種された乳酸菌の菌株を培養させる段階;を含むことを特徴とする食物繊維が豊富なプロバイオティクス組成物の製造方法を提供する。
A fourth aspect of the present application is
A probiotic rich in dietary fiber, comprising: inoculating the prebiotic composition prepared in the third aspect of the present application with a strain of lactic acid bacteria; and culturing the inoculated strain of lactic acid bacteria. Kind Code: A1 A method for making a toxic composition is provided.
本願の第1側面及び第2側面と重複される部分たちに対しては詳細な説明を省略したが、本願の第1側面及び第2側面に対して説明した内容は第3側面及び第4側面でその説明が省略されたとしても同一に適用できる。 Although detailed descriptions of the parts that overlap with the first and second aspects of the present application have been omitted, the content described with respect to the first and second aspects of the present application is the third and fourth aspects. Even if the explanation is omitted in , the same can be applied.
以下、本願の第3側面に従った食物繊維が豊富なプレバイオティクス組成物の製造方法及び本願の第4側面に従った食物繊維が豊富なプロバイオティクス組成物の製造方法を図1及び2を参照して詳細に説明する。この時、前記図1はプレバイオティクス組成物の製造方法を概略的に表したフローチャートであり、図2はプロバイオティクス組成物の製造方法を概略的に表したフローチャートである。 A method for producing a dietary fiber-rich prebiotic composition according to the third aspect of the present application and a method for producing a dietary fiber-rich probiotic composition according to the fourth aspect of the present application are shown below in FIGS. will be described in detail with reference to. At this time, FIG. 1 is a flow chart schematically showing a method for preparing a prebiotic composition, and FIG. 2 is a flow chart schematically showing a method for preparing a probiotic composition.
先ず、本願の一具現例にあって、前記プレバイオティクス組成物の製造方法はキノコ及び精製水の混合物を抽出器に投入させて80℃乃至120℃の温度で1次抽出させる段階;(S100)を含むものであることができる。 First, in an embodiment of the present application, the method for preparing the prebiotic composition includes the step of introducing a mixture of mushrooms and purified water into an extractor and performing primary extraction at a temperature of 80° C. to 120° C. (S100). ).
本願の一具現例にあって、前記抽出器は一般的に抽出を行う機器を使用することがあり、前記抽出は好ましく熱水抽出であるものであることができる。一方、前記1次抽出段階は80℃乃至120℃の温度で1時間乃至3時間の間行うことがあり、好ましく約100℃の温度で約2時間の間行うものであることができる。又、前記1次抽出を行った後、前記混合物を1次冷却させることであることがあるし、この時前記冷却は常温の温度で約1時間の間放冷させることで行われるものであることができる。 In one embodiment of the present application, the extractor may use a general extraction device, and the extraction may preferably be hot water extraction. Meanwhile, the first extraction step may be performed at a temperature of 80° C. to 120° C. for 1 hour to 3 hours, preferably at a temperature of about 100° C. for about 2 hours. Also, after performing the primary extraction, the mixture may be primary cooled, and the cooling may be performed by allowing the mixture to cool at room temperature for about 1 hour. be able to.
本願の一具現例にあって、前記キノコはマンネンタケを含むことでありうるし、前記マンネンタケは図3a及び3bに表した通り、他のキノコや食品に比べて高い総食物繊維含有量を持つためこれを含む前記プレバイオティクス組成物が豊富な食物繊維含有量を有するものであることができる。一方、前記マンネンタケは不溶性食物繊維に比べて桁外れに高い水溶性食物繊維含有量を持つため高い生理活性を有するものであることができる。 In one embodiment of the present application, the mushroom may include Ganoderma lucidum, which has a higher total dietary fiber content than other mushrooms and food products, as shown in FIGS. 3a and 3b. The prebiotic composition comprising can have a rich dietary fiber content. On the other hand, since the Ganoderma lucidum has a much higher water-soluble dietary fiber content than insoluble dietary fiber, it may have high physiological activity.
本願の一具現例にあって、前記キノコは前記マンネンタケの他に、椎茸、エリンギ、エノキタケ、ヒラタケ、マッシュルーム、メシマコブ、ブナシメジ、ハナビラタケ、カバノアナタケ、ヤマブシタケ及びこれらの組み合わせからなる群から選択されるキノコを更に含むことでありうるし、好ましく椎茸及びエリンギを更に含むものであることができる。即ち、本願の一実施例によると前記プレバイオティクス組成物の製造方法に使用されるキノコはマンネンタケ、椎茸及びエリンギであることができる。この場合、前記マンネンタケ1重量部対比前記椎茸の含量は5重量部乃至20重量部でありうるし、前記エリンギの含量は50重量部乃至200重量部であるものであることができる。好ましく本願の一実施例に従うと前記マンネンタケ1重量部対比前記椎茸の含量は10重量部であり、前記エリンギの含量は100重量部であるものであることができる。 In one embodiment of the present application, in addition to the Ganoderma lucidum, the mushroom is a mushroom selected from the group consisting of shiitake, eryngii, enokitake, oyster mushroom, mushroom, Korean mushroom, bunashimeji, sparassis crispa, birch anatake, ericaceae, and combinations thereof. It may further contain shiitake mushrooms and king oyster mushrooms. That is, according to one embodiment of the present application, the mushrooms used in the method for preparing the prebiotic composition may be Ganoderma lucidum, shiitake mushroom and king oyster mushroom. In this case, the content of the shiitake mushroom may be 5 to 20 parts by weight, and the content of the king oyster mushroom may be 50 to 200 parts by weight based on 1 part by weight of the Ganoderma lucidum. Preferably, according to an embodiment of the present application, the content of the shiitake mushroom is 10 parts by weight, and the content of the king oyster mushroom is 100 parts by weight, based on 1 part by weight of the Ganoderma lucidum.
次に、本願の一具現例にあって、前記プレバイオティクス組成物の製造方法は前記1次抽出させた混合物を60℃乃至100℃の温度で2次抽出させる段階;(S200)を含むものであることができる。 Next, in an embodiment of the present application, the method for preparing the prebiotic composition includes second extraction of the first-extracted mixture at a temperature of 60° C. to 100° C. (S200). be able to.
本願の一具現例にあって、前記2次抽出は好ましく熱水抽出でありうるし、前記2次抽出段階は60℃乃至100℃の温度で1時間乃至3時間の間行うことがあり、好ましく約80℃の温度で約2時間の間行うものであることができる。又、前記2次抽出を行った後、前記混合物を2次冷却させることであることがあるし、この時前記冷却は常温の温度で約1時間の間放冷させることで行われるものであることができる。 In an embodiment of the present application, the secondary extraction may preferably be hot water extraction, and the secondary extraction step may be performed at a temperature of 60° C. to 100° C. for 1 hour to 3 hours, preferably about It can be carried out at a temperature of 80° C. for about 2 hours. Also, after the second extraction, the mixture may be secondarily cooled. At this time, the cooling may be performed by allowing the mixture to cool at room temperature for about one hour. be able to.
次に、本願の一具現例にあって、前記プレバイオティクス組成物の製造方法は前記2次抽出させた混合物を40℃乃至80℃の温度で3次抽出させてキノコ抽出物を製造する段階;(S300)を含むものであることができる。 Next, according to an embodiment of the present application, the method for preparing the prebiotic composition includes the step of subjecting the secondary-extracted mixture to a tertiary extraction at a temperature of 40° C. to 80° C. to prepare a mushroom extract. ; (S300).
本願の一具現例にあって、前記3次抽出は好ましく熱水抽出でありうるし、前記3次抽出段階は40℃乃至80℃の温度で1時間乃至3時間の間行うことがあり、好ましく約60℃の温度で約2時間の間行うものであることができる。又、前記3次抽出を行った後、前記混合物を3次冷却させることであることがあるし、この時前記冷却は常温の温度で約15時間の間放冷させることで行われるものであることができる。 In an embodiment of the present application, the tertiary extraction may preferably be hot water extraction, and the tertiary extraction step may be performed at a temperature of 40° C. to 80° C. for 1 to 3 hours, preferably about It can be carried out at a temperature of 60° C. for about 2 hours. Also, after the tertiary extraction, the mixture may be tertiary cooled. At this time, the cooling may be performed by allowing the mixture to stand at room temperature for about 15 hours. be able to.
次に、本願の一具現例にあって、前記プレバイオティクス組成物の製造方法は前記製造されたキノコ抽出物に原乳、粉乳、糖及びこれらの組み合わせからなる群から選択される物質を含む添加剤を混合した後均質化してプレバイオティクス組成物を製造する段階;(S400)を含むものであることができる。 Next, in an embodiment of the present application, the method for preparing the prebiotic composition includes a substance selected from the group consisting of raw milk, powdered milk, sugar and combinations thereof in the prepared mushroom extract. (S400) of mixing additives and then homogenizing to produce a prebiotic composition;
本願の一具現例にあって、前記添加剤は前記キノコ抽出物と混合されて、均質化されることで乳酸菌培養組成物、即ちプレバイオティクス組成物を成すものであることができる。この時、前記キノコ抽出物の含量は前記添加剤100重量部対比400重量部乃至600重量部でありうるし、好ましく400重量部乃至500重量部でありうるし、より好ましくは450重量部乃至500重量部であるものであることができる。一方、前記キノコ抽出物の含量が前記添加剤100重量部対比400重量部未満である場合前記キノコ抽出物の含量が相対的に少なく、これを含むプレバイオティクス組成物が食物繊維を少なく含有できるし、600重量部超過である場合前記添加剤の含量が相対的に少なく、追って乳酸菌培養に難しさが発生することがある。本願の一実施例に従うと前記キノコ抽出物の含量は前記添加剤100重量部対比約487重量部であるものであることができる。 In one embodiment of the present application, the additive may be mixed with the mushroom extract and homogenized to form a lactic acid bacteria culture composition, ie, a prebiotic composition. At this time, the content of the mushroom extract may be 400 to 600 parts by weight, preferably 400 to 500 parts by weight, more preferably 450 to 500 parts by weight, based on 100 parts by weight of the additive. can be what is On the other hand, when the content of the mushroom extract is less than 400 parts by weight based on 100 parts by weight of the additive, the content of the mushroom extract is relatively low, and the prebiotic composition containing the mushroom extract may contain less dietary fiber. However, if it exceeds 600 parts by weight, the content of the additive is relatively small, which may cause difficulty in culturing lactic acid bacteria. According to one embodiment of the present application, the content of the mushroom extract may be about 487 parts by weight based on 100 parts by weight of the additive.
本願の一具現例にあって、前記添加剤は前記した物質たちの他にチコリ抽出物、デキストリン、精製水及びこれらの組み合わせからなる群から選択される物質を更に含むものであることができる。以下、前記添加剤に含まれる物質の具体的な種類及び含量範囲に対しては前記本願の第1側面及び第2側面で詳細に説明しているので以下具体的な説明を省略することにする。 In one embodiment of the present application, the additive may further include a material selected from the group consisting of chicory extract, dextrin, purified water, and combinations thereof, in addition to the above materials. Hereinafter, since the specific types and content ranges of the substances contained in the additive have been described in detail in the first and second aspects of the present application, detailed descriptions thereof will be omitted. .
次に、本願の一具現例にあって、前記プロバイオティクス組成物の製造方法は前記製造したプレバイオティクス組成物に乳酸菌の菌株を接種させる段階;(S500)及び前記接種された乳酸菌の菌株を培養させる段階;(S600)を含むものであることができる。 Next, in an embodiment of the present application, the method for preparing the probiotic composition includes inoculating the prepared prebiotic composition with a strain of lactic acid bacteria; (S500) and the inoculated strain of lactic acid bacteria. culturing; (S600).
本願の一具現例にあって、前記プレバイオティクス組成物に乳酸菌の菌株を接種させる前に、製造したプレバイオティクス組成物を約100℃の温度で1時間の間滅菌処理して、約30℃乃至40℃の温度で冷却させた後乳酸菌の菌株を接種させることであることができる。以後乳酸菌の菌株を接種したプレバイオティクス組成物を恒温培養器で約5時間乃至8時間くらい発酵させた後、5℃以下の温度で熟成させることでプロバイオティクス組成物を製造するものであることができる。 In one embodiment of the present application, the prebiotic composition prepared is sterilized at a temperature of about 100° C. for 1 hour, and then sterilized for about 30 minutes before inoculating the prebiotic composition with a strain of lactic acid bacteria. C. to 40.degree. C. and then inoculating the strain of lactic acid bacteria. Thereafter, the prebiotic composition inoculated with the lactic acid bacteria strain is fermented in a constant temperature incubator for about 5 to 8 hours, and then aged at a temperature of 5° C. or less to produce a probiotic composition. be able to.
本願の一具現例にあって、前記乳酸菌の菌株はラクトバチルス(Lactobacillus)、ストレプトコッカスサーモフィルス(Streptococcus thermophilus)、ビフィズス菌(Bifidobacterium)、複合乳酸菌ABT-B菌株及びこれらの組み合わせからなる群から選択される乳酸菌の菌株を含むことがあり、本願の一実施例に従うと前記乳酸菌の菌株は複合乳酸菌ABT-B菌株であるものであることができる。 In one embodiment of the present application, the strain of lactic acid bacteria is selected from the group consisting of Lactobacillus, Streptococcus thermophilus, Bifidobacterium, ABT-B complex lactic acid bacteria strain, and combinations thereof. and according to one embodiment of the present application, the lactic acid bacterium strain may be a complex lactic acid bacterium ABT-B strain.
本願の一具現例にあって、前記接種される乳酸菌の菌株の含量は前記キノコ抽出物100重量部対比0.01重量部乃至0.1重量部でありうるし、本発明の一実施例に従うと約0.042重量部であるものであることができる。 In one embodiment of the present application, the content of the inoculated lactic acid bacteria strain may be 0.01 to 0.1 parts by weight based on 100 parts by weight of the mushroom extract, and according to an embodiment of the present invention, It can be about 0.042 parts by weight.
本発明に従う、プレバイオティクス組成物は3次抽出したキノコ抽出物を含むことで豊富な食物繊維を有するものであることができる。又、前記キノコ抽出物に含まれた食物繊維は不溶性食物繊維だけではなく生理活性機能を持つ水溶性食物繊維を多量含有するものであることができる。従って、前記プレバイオティクス組成物を摂取する場合、豊富な食物繊維によって便通を大きく向上させる効果を有するものであることができる。 A prebiotic composition according to the present invention can be rich in dietary fiber by including a tertiary extracted mushroom extract. Also, the dietary fiber contained in the mushroom extract may contain a large amount of not only insoluble dietary fiber but also water-soluble dietary fiber having physiologically active functions. Therefore, when the prebiotic composition is ingested, it may have the effect of greatly improving bowel movements due to its rich dietary fiber.
又、前記プレバイオティクス組成物に乳酸菌の菌株を接種して培養する場合、より優れた乳酸菌増殖率を表するものであることができる。これに従って前記プレバイオティクス組成物に乳酸菌の菌株を接種して培養したプロバイオティクス組成物は豊富な乳酸菌の菌株を保有するものであることができる。従って、前記プロバイオティクス組成物は乳酸菌の整腸作用及び免疫力向上等の効能だけではなく食物繊維による血糖上昇抑制及び血中コレストロール数値降下効果等抗肥満効果を表するものであることができる。 In addition, when the prebiotic composition is inoculated with a lactic acid bacterium strain and cultured, it may exhibit a better lactic acid bacterium growth rate. According to this, the probiotic composition obtained by inoculating and culturing the prebiotic composition with a lactic acid bacterium strain can contain abundant lactic acid bacterium strains. Therefore, the probiotic composition can exhibit not only the effect of lactic acid bacteria for regulating the intestines and improving immunity, but also the anti-obesity effect such as the suppression of blood sugar elevation and blood cholesterol level lowering effect due to dietary fiber. .
Claims (15)
前記キノコ抽出物はマンネンタケ抽出物を含み、
前記添加剤は原乳、粉乳、糖及びこれらの組み合わせからなる群から選択される物質を含み、
前記プレバイオティクス組成物は前記キノコ抽出物100重量部に対する食物繊維の含量比が30重量部以上であることを特徴とする食物繊維が豊富なプレバイオティクス組成物。 A prebiotic composition comprising a mushroom extract and an additive,
the mushroom extract comprises a Ganoderma lucidum extract;
the additive comprises a substance selected from the group consisting of raw milk, powdered milk, sugar and combinations thereof;
A prebiotic composition rich in dietary fiber, wherein the prebiotic composition contains 30 parts by weight or more of dietary fiber relative to 100 parts by weight of the mushroom extract.
前記食物繊維全体100重量部に対する前記水溶性食物繊維の含量比は40重量部~80重量部であり、前記不溶性食物繊維の含量比は20重量部~60重量部であることを特徴とする、請求項1に記載の食物繊維が豊富なプレバイオティクス組成物。 The dietary fiber includes water-soluble dietary fiber and insoluble dietary fiber,
The content ratio of the water-soluble dietary fiber to 100 parts by weight of the total dietary fiber is 40 parts by weight to 80 parts by weight, and the content ratio of the insoluble dietary fiber is 20 parts by weight to 60 parts by weight. 2. The dietary fiber-rich prebiotic composition of claim 1.
椎茸、エリンギ、エノキタケ、ヒラタケ、マッシュルーム、メシマコブ、ブナシメジ、ハナビラタケ、カバノアナタケ、ヤマブシタケ及びこれらの組み合わせからなる群から選択されるキノコの抽出物を更に含むことを特徴とする、請求項1に記載の食物繊維が豊富なプレバイオティクス組成物。 The mushroom extract, in addition to the Ganoderma lucidum extract,
2. The food of claim 1, further comprising an extract of a mushroom selected from the group consisting of shiitake, eryngii, enokitake, oyster mushroom, mushroom, Korean mushroom, bunashimeji, sparassis crispa, birch anatake, ericaceae and combinations thereof. Prebiotic composition rich in fiber.
前記1次抽出させた混合物を60℃~100℃の温度で2次抽出させる段階;
前記2次抽出させた混合物を40℃~80℃の温度で3次抽出させてキノコ抽出物を製造する段階;及び
前記製造されたキノコ抽出物に原乳、粉乳、糖及びこれらの組み合わせからなる群から選択される物質を含む添加剤を混合した後均質化してプレバイオティクス組成物を製造する段階;
を含むことを特徴とする食物繊維が豊富なプレバイオティクス組成物の製造方法。 Inputting a mixture of mushrooms and purified water into an extractor for primary extraction at a temperature of 80° C. to 120° C.;
secondly extracting the firstly extracted mixture at a temperature of 60° C. to 100° C.;
tertiary extraction of the secondary extracted mixture at a temperature of 40° C. to 80° C. to prepare a mushroom extract; and raw milk, powdered milk, sugar, and a combination thereof in the prepared mushroom extract mixing and then homogenizing an additive comprising a substance selected from the group to produce a prebiotic composition;
A method for producing a dietary fiber-rich prebiotic composition comprising:
前記接種された乳酸菌の菌株を培養させる段階;
を含むことを特徴とする食物繊維が豊富なプロバイオティクス組成物の製造方法。
inoculating the prebiotic composition of claim 12 with a strain of lactic acid bacteria; and culturing the inoculated strain of lactic acid bacteria;
A method for producing a dietary fiber-rich probiotic composition comprising:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200104989A KR102526878B1 (en) | 2020-08-21 | 2020-08-21 | Prebiotics composition rich in dietary fiber including mushroom extract and probiotics composition including thereof |
KR10-2020-0104989 | 2020-08-21 | ||
PCT/KR2020/016549 WO2022039326A1 (en) | 2020-08-21 | 2020-11-23 | Dietary fiber-rich prebiotics composition comprising mushroom extract, and probiotics composition comprising same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022548803A true JP2022548803A (en) | 2022-11-22 |
JP7434298B2 JP7434298B2 (en) | 2024-02-20 |
Family
ID=80322938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021516768A Active JP7434298B2 (en) | 2020-08-21 | 2020-11-23 | Prebiotic composition rich in dietary fiber containing mushroom extract and probiotic composition containing same |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP7434298B2 (en) |
KR (1) | KR102526878B1 (en) |
WO (1) | WO2022039326A1 (en) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5157858A (en) * | 1974-11-15 | 1976-05-20 | Shigenobu Watari | Nyusankininryono seizohoho |
JPS61195669A (en) * | 1985-02-22 | 1986-08-29 | Osaka Chem Lab | Health food made from fomes japonicus |
JPH01206970A (en) * | 1987-10-20 | 1989-08-21 | Kureha Chem Ind Co Ltd | Novel food |
JPH02283240A (en) * | 1989-04-25 | 1990-11-20 | Masasuke Kanetani | Production of milk fermentation food product using mushrooms |
JPH06153859A (en) * | 1992-11-25 | 1994-06-03 | Koujiyouen:Kk | Food containing large amount of fat and compounded with component of fomes japonicus |
JPH0812587A (en) * | 1994-06-30 | 1996-01-16 | Shinatsushin Clinic:Kk | Method for aggregating cow's milk into yogurt state with powder of fomes japonicus |
JP2002336907A (en) * | 2001-05-11 | 2002-11-26 | Daido Steel Co Ltd | Method and apparatus for rolling wire rod |
JP2003040785A (en) * | 2001-05-21 | 2003-02-13 | Combi Corp | Infection suppressing composition and food and drink containing the same |
JP2014221720A (en) * | 2013-05-13 | 2014-11-27 | 株式会社リンクス | Restoration agent for hematopoietic injury caused by radiation |
JP2015123072A (en) * | 2013-12-27 | 2015-07-06 | 焼津水産化学工業株式会社 | METHOD FOR PRODUCING β-GLUCAN-CONTAINING COMPOSITION CONTAINING BASIDIOMYCETE AS RAW MATERIAL |
KR20190073652A (en) * | 2017-12-19 | 2019-06-27 | 주식회사 에코비오스 | Culture medium composition for lactobacillus using dry shitake mushroom extract |
JP2020512837A (en) * | 2017-04-10 | 2020-04-30 | キボー バイオテック、インクKibow Biotech, Inc. | Multi-fiber prebiotic composition for digestive health, weight management, immune enhancement and improved health |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100378154B1 (en) * | 2000-06-05 | 2003-03-29 | 신갑균 | A functional yogurt using a mushroom and process for preparation thereof |
KR100534066B1 (en) * | 2001-09-04 | 2005-12-06 | 주식회사 바이오허브 | Mushroom lactic acid fermented solution including effective ingredients for decreasing the value of blood sugar, and method for manufacturing the solution |
KR100445685B1 (en) * | 2001-05-07 | 2004-08-21 | 신갑균 | Medium composition for lactobacillus comprising mushroom powder or mushroom extracts, composition of mushroom lactic acid fermentation using the medium composition, and method for manufacturing the composition of mushroom lactic acid fermentation |
KR101519606B1 (en) * | 2013-05-29 | 2015-05-12 | 세종대학교산학협력단 | Rice dough with the dietary fiber of mushroom and rice noodle therefrom |
KR101513712B1 (en) * | 2013-06-27 | 2015-04-22 | (주)새롬바이오 | A preparation method for extract of fermented sparassis crispa which has increased soluble dietary fiber |
-
2020
- 2020-08-21 KR KR1020200104989A patent/KR102526878B1/en active IP Right Grant
- 2020-11-23 WO PCT/KR2020/016549 patent/WO2022039326A1/en active Application Filing
- 2020-11-23 JP JP2021516768A patent/JP7434298B2/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5157858A (en) * | 1974-11-15 | 1976-05-20 | Shigenobu Watari | Nyusankininryono seizohoho |
JPS61195669A (en) * | 1985-02-22 | 1986-08-29 | Osaka Chem Lab | Health food made from fomes japonicus |
JPH01206970A (en) * | 1987-10-20 | 1989-08-21 | Kureha Chem Ind Co Ltd | Novel food |
JPH02283240A (en) * | 1989-04-25 | 1990-11-20 | Masasuke Kanetani | Production of milk fermentation food product using mushrooms |
JPH06153859A (en) * | 1992-11-25 | 1994-06-03 | Koujiyouen:Kk | Food containing large amount of fat and compounded with component of fomes japonicus |
JPH0812587A (en) * | 1994-06-30 | 1996-01-16 | Shinatsushin Clinic:Kk | Method for aggregating cow's milk into yogurt state with powder of fomes japonicus |
JP2002336907A (en) * | 2001-05-11 | 2002-11-26 | Daido Steel Co Ltd | Method and apparatus for rolling wire rod |
JP2003040785A (en) * | 2001-05-21 | 2003-02-13 | Combi Corp | Infection suppressing composition and food and drink containing the same |
JP2014221720A (en) * | 2013-05-13 | 2014-11-27 | 株式会社リンクス | Restoration agent for hematopoietic injury caused by radiation |
JP2015123072A (en) * | 2013-12-27 | 2015-07-06 | 焼津水産化学工業株式会社 | METHOD FOR PRODUCING β-GLUCAN-CONTAINING COMPOSITION CONTAINING BASIDIOMYCETE AS RAW MATERIAL |
JP2020512837A (en) * | 2017-04-10 | 2020-04-30 | キボー バイオテック、インクKibow Biotech, Inc. | Multi-fiber prebiotic composition for digestive health, weight management, immune enhancement and improved health |
KR20190073652A (en) * | 2017-12-19 | 2019-06-27 | 주식회사 에코비오스 | Culture medium composition for lactobacillus using dry shitake mushroom extract |
Non-Patent Citations (1)
Title |
---|
化学と生物, vol. 23(12), JPN6022053471, 1985, pages 797 - 802, ISSN: 0005045484 * |
Also Published As
Publication number | Publication date |
---|---|
JP7434298B2 (en) | 2024-02-20 |
KR20220023356A (en) | 2022-03-02 |
WO2022039326A1 (en) | 2022-02-24 |
KR102526878B1 (en) | 2023-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11291697B2 (en) | Probiotic composition and use thereof | |
EP0486738B1 (en) | Method of preparing milk-fermented food | |
JP5000066B2 (en) | Conversion and modification of natural drugs by co-fermentative culture of intestinal symbiotic organisms | |
US20090285936A1 (en) | New functional fermented milk (yogurt) for use in dieting | |
CN112244299B (en) | Probiotic composition with function of relieving nonalcoholic fatty liver and preparation method thereof | |
CN104542977A (en) | Health beverage containing dioscorease rhizome extract and bifidobacterium bifidum and preparation method of health beverage | |
CN111955548B (en) | Pure probiotic flavored fermented milk and preparation method thereof | |
WO2019153334A1 (en) | Complex prebiotics regulating human intestinal function and use thereof | |
KR20040027180A (en) | Lactic Acid Bacteria-Fermenting Dairy Products Used for Preventing and Treating Obesity or Diabetes Mellitus and Manufacturing Method thereof | |
JP3644500B2 (en) | Method for producing mushroom lactic acid fermented liquid and mushroom lactic acid fermented liquid produced therefrom | |
CN101223911A (en) | Mushroom acid milk and preparing process thereof | |
CN110484459B (en) | Lactobacillus plantarum and application thereof | |
CN108795823B (en) | It is a kind of improve women pregnant and lying-in women's intestinal flora probiotics cultural method and application | |
KR20130021346A (en) | A yogurt for improving constipation prepared by mixed fermentation steps and the method thereof | |
KR102182076B1 (en) | Culture medium composition for lactobacillus comprising mushroom extract, fermented composition thereof, and a method for preparing the same | |
CN111228316B (en) | Composite probiotics for improving diabetes | |
CN111035658A (en) | Use of pediococcus pentosaceus | |
JPH059124A (en) | Composition for regulating interleukin productivity | |
JP7434298B2 (en) | Prebiotic composition rich in dietary fiber containing mushroom extract and probiotic composition containing same | |
CN110982731A (en) | Space-induced lactobacillus plantarum ST20-71 with probiotic characteristics and application thereof | |
CN109169899A (en) | A kind of preparation method of the shield stomach acidified milk containing Hericium erinaceus beta glucan | |
JP4851765B2 (en) | Immune function regulator | |
TWI593352B (en) | A kind of black garlic fermented milk for antioxidant ability/free radical scavenging capacity with its manufacture method. | |
JP4011938B2 (en) | Lipid metabolism improving agent and food containing the same | |
CN112841308A (en) | Preparation method and application of hericium erinaceus composition with gastric mucosa protecting effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210319 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230320 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230425 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230720 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231019 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240109 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240207 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7434298 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |